Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

2.

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.

Stagg NJ, Shen BQ, Brunstein F, Li C, Kamath AV, Zhong F, Schutten M, Fine BM.

Regul Toxicol Pharmacol. 2016 Dec;82:1-13. doi: 10.1016/j.yrtph.2016.10.012. Epub 2016 Oct 20. Review.

PMID:
27773754
3.

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G.

Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693. Epub 2016 Jan 28.

4.

Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.

van Etten B, de Wilt JH, Brunstein F, Eggermont AM, Verhoef C.

Eur J Surg Oncol. 2009 May;35(5):539-45. doi: 10.1016/j.ejso.2008.07.004. Epub 2008 Aug 28.

PMID:
18760560
5.

Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.

Verhoef C, de Wilt JH, Brunstein F, Marinelli AW, van Etten B, Vermaas M, Guetens G, de Boeck G, de Bruijn EA, Eggermont AM.

Ann Surg Oncol. 2008 May;15(5):1367-74. doi: 10.1245/s10434-007-9714-z. Epub 2008 Feb 1.

6.

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.

Brunstein F, Rens J, van Tiel ST, Eggermont AM, ten Hagen TL.

Br J Cancer. 2006 Dec 18;95(12):1663-9. Epub 2006 Nov 14.

7.

Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.

Brunstein F, Eggermont AM, de Wiel-Ambagtsheer Ga, van Tiel ST, Rens J, ten Hagen TL.

Ann Surg Oncol. 2007 Feb;14(2):795-801. Epub 2006 Nov 10.

PMID:
17096052
8.

Telomerase activity in prognostic histopathologic features of melanoma.

Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, Ferreira L.

J Plast Reconstr Aesthet Surg. 2006;59(9):961-8. Epub 2006 Apr 3.

PMID:
16920589
9.

Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.

Brunstein F, Hoving S, aan de Wiel-Ambagtsheer G, de Bruijn EA, Guetens G, Eggermont AM, ten Hagen TL.

Cancer Immunol Immunother. 2007 Apr;56(4):573-80. Epub 2006 Aug 1.

PMID:
16896966
10.

Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.

van Horssen R, Rens JA, Brunstein F, Guns V, van Gils M, Hagen TL, Eggermont AM.

Int J Cancer. 2006 Sep 15;119(6):1481-90.

11.

Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.

Brunstein F, Santos ID, Ferreira LM, van Tiel ST, Eggermont AM, Ten Hagen TL.

Acta Cir Bras. 2005 Jul-Aug;20(4):275-9. Epub 2005 Jul 18.

12.

Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.

Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM.

Ann Surg Oncol. 2005 Aug;12(8):609-15. Epub 2005 Jun 22.

PMID:
15968498
13.

Bio-chemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques.

van Ijken MG, van Etten B, Brunstein F, ten Hagen TL, Guetens G, de Wilt JH, de Bruijn EA, Eggermont AM.

Eur J Surg Oncol. 2005 Oct;31(8):807-16. Review.

PMID:
15951150
14.

Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.

Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL.

Cancer Res. 2005 May 15;65(10):4300-8.

15.

Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.

Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM.

Ann Surg Oncol. 2005 Jun;12(6):473-9. Epub 2005 Apr 19.

PMID:
15864484
16.

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM.

Ann Surg. 2004 Dec;240(6):939-47; discussion 947-8.

17.

Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL.

J Natl Cancer Inst. 2004 Nov 3;96(21):1603-10.

PMID:
15523089
18.

Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage.

Eggermont AM, Brunstein F, Grünhagen D, ten Hagen TL.

Ann Oncol. 2004;15 Suppl 4:iv107-12. Review. No abstract available.

PMID:
15477292
19.

TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.

Grünhagen DJ, Brunstein F, ten Hagen TL, van Geel AN, de Wilt JH, Eggermont AM.

Cancer Treat Res. 2004;120:65-79. Review. No abstract available.

PMID:
15217218
20.

Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.

van Etten B, Brunstein F, van IJken MG, Marinelli AW, Verhoef C, van der Sijp JR, Guetens G, de Boeck G, de Bruijn EA, de Wilt JH, Eggermont AM.

Ann Surg Oncol. 2004 Jun;11(6):598-605.

PMID:
15172933
21.

A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma.

Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa D Jr.

Int J Dermatol. 2003 Feb;42(2):153-6.

PMID:
12709008
22.

Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response.

Christoforidis D, Chassot PG, Mosimann F, Lienard D, Brunstein F, Bejko D, Lejeune FJ, Chiolero R.

Arch Surg. 2003 Jan;138(1):17-25.

PMID:
12511144
23.

V-Y advancement flap for the reconstruction of partial and full thickness defects of the upper lip.

Carvalho LM, Ramos RR, Santos ID, Brunstein F, Lima AH, Ferreira LM.

Scand J Plast Reconstr Surg Hand Surg. 2002;36(1):28-33.

PMID:
11925826

Supplemental Content

Loading ...
Support Center